TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02787382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echocardiographic examination
Description: Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echocardiographic examination
Description: Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection.
Study: NCT03836248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: 5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham osteopathic treatment
Description: 5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Current practice Medication treatment
Description: Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Current practice Medication treatment
Description: Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current practice Medication treatment
Description: Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
Study: NCT03094429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaBen®
Description: 2000 mg/day or 1000 mg/day, twice daily
Study: NCT00300456

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for placebo information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for placebo information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for placebo information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for placebo information
Study: NCT00728845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 200 mg orally BID (total daily dose of 400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 200 mg orally BID (total daily dose of 400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Dose of 200 mg/m2 IV on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Dose of 200 mg/m2 IV on day 1 of each cycle
Study: NCT02667730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500 mg four times daily for 7 days
Study: NCT01291329

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intracoronary human umbilical WJ-MSC transfer
Description: intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
Study: NCT03071224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] MNI-946
Description: Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetapir
Description: Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
Study: NCT02146079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
Study: NCT02667730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: naproxen 500mg twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 100mg twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy only
Description: physiotherapy only (no drug)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy only
Description: physiotherapy only (no drug)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy only
Description: physiotherapy only (no drug)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiotherapy only
Description: physiotherapy only (no drug)
Study: NCT02146079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
Study: NCT00879814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086 vaccine or control
Description: intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086 vaccine or control
Description: intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086 vaccine or control
Description: intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rLP2086 vaccine or control
Description: intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
Study: NCT02855411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm
Study: NCT02191618

Intervention type: DEVICE
Group type: OTHER
Intervention: WEB
Description: The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
Study: NCT00939627

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01047891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
Study: NCT02040519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Filling out voiding diaries.
Study: NCT03328429

Intervention type: OTHER
Group type: OTHER
Intervention: Excision
Description: Bartholin gland will be excised
Study: NCT03094429

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg total, twice daily
Study: NCT00876057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total abdominal hysterectomy
Description: Total abdominal hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtotal abdominal hysterectomy
Description: Subtotal abdominal hysterectomy
Study: NCT00438555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and children group
Description: 3 months workshops of parents and children intervention, guided by dietician and phycologist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent's group
Description: 3 months workshop of parents intervention, guided by dietician and phycologist
Study: NCT02952755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20162
Study: NCT04226469

Intervention type: PROCEDURE
Intervention: Tooth movement
Description: The subject's canines will be retracted distally and crevicular fluid is collected
Study: NCT02703129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
Study: NCT04455009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fitness Drink Formula
Description: Single drink provided following baseline assessments

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fitness Drink Formula
Description: Single drink provided following baseline assessments

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fitness Drink Formula
Description: Single drink provided following baseline assessments
Study: NCT01787994

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.
Study: NCT01202851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Program
Description: 3 times a week, 60 minute sessions for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Program
Description: 3 times a week, 60 minute sessions for 6 weeks.
Study: NCT02855411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, twice daily (BID) for 12 weeks, capsule
Study: NCT01281852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00907881

Intervention type: DRUG
Intervention: Sulfonylurea
Description: The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
Study: NCT01936285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03328429

Intervention type: OTHER
Group type: OTHER
Intervention: Marsupialization
Description: Bartholin gland will be marsupialised
Study: NCT03779568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose adjustment of bupivacaine
Description: Spinal bupivacaine dose will be adjusted according to previous patient experience.
Study: NCT02007785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP treatment protocol
Description: Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
Study: NCT04460378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy with Focus on guided exposure
Study: NCT01989546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
Study: NCT00587821

Intervention type: OTHER
Intervention: Blood draw
Description: Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.

Intervention type: OTHER
Intervention: Blood draw
Description: Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
Study: NCT02955654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress management training
Description: Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
Study: NCT03869957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
Study: NCT00190203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy and duraplasty
Description: Decompressive hemicraniectomy and duraplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemicraniectomy
Description: hemicraniectomy
Study: NCT04129684

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: subgingival delivery and lozenges

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: subgingival delivery and lozenges
Study: NCT04242017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptoreline
Description: Comparison of the duration of ADT (Triptoreline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptoreline
Description: Comparison of the duration of ADT (Triptoreline)
Study: NCT04042610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Prompt for Interrupting Sitting Time
Description: An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
Study: NCT01477697

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: 50 mg/kg per day of omega-3 fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg/kg per day of placebo equivalent
Study: NCT03462446

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians

Intervention type: DRUG
Intervention: Vitamin K antagonists (VKAs)
Description: As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
Study: NCT00110656

Intervention type: OTHER
Intervention: Observations
Description: This is a non-interventional study- only observational.
Study: NCT03614533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Description: Single 0.5-ml intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliovirus Vaccine (IPV)
Description: Single 0.5-ml intramuscular injection
Study: NCT00784030

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
Study: NCT02360306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Ultrasound
Description: Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound
Description: Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
Study: NCT02106533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.